Publications
Learn from our experts.
Meeting your needs is our priority!
Publications from VelaLabs experts
Surface Plasmon Resonance for Determination of Potency.
Gaderer, S. (2022). Pharm. Ind. 84, Nr. 7, 909–917 (2022) © ECV • Editio Cantor Verlag, Aulendorf (Germany).
Insight into biosimilars: Short description, analytical assessment and market.
Zimmermann, K, Fido, M, and Roucka, M. (2020). Medical Research Archives 8: issue 3.
Glycosylation pattern of biotechnologically produced proteins – lectin array technology as a versatile tool for screening?
Zimmermann, K, Fido, M, and Roucka, M. (2018). Medical Research Archives 6: issue 3.
Application of lectin array technology for biobetter characterization: its correlation with FcγRIII binding and ADCC. Microarrays.
Roucka, M, Zimmermann, K, Fido, M, and Nechansky, A. (2017). 6:1.
Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection.
Zopf, A, Raim, R, Danzer, M, Niklas, N, Spilka, R, Pröll, J, Gabriel, C, Nechansky, A, and Roucka, M. (2015). Biotechniques. 58:126-134.
Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.
Kircheis, R, Halanek, N, Koller, I, Jost, W, Schuster, M, Gorr, G, Hajszan, K, and Nechansky, A. (2012). MAbs. 4:532-541.
Immunogenicity of therapeutics: a matter of efficacy and safety.
Nechansky, A, and Kircheis R. (2010). Drug Discov. 5:1-13.
Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.
Nechansky, A. (2010). HAHA – nothing to laugh about. J. Pharm. Biomed. Anal. 51:252-254.
For reprints please contact us HERE